Recursion stock jumps on strong Q4 results

Biotech firm beats Wall Street expectations, driven by milestone payment from Roche partnership

Feb. 25, 2026 at 4:42pm

Got story updates? Submit your updates here. ›

Shares of Recursion Pharmaceuticals (RXRX) surged after the company reported Q4 2025 financial results that significantly exceeded Street forecasts. The strong performance was primarily driven by a milestone payment from the company's partnership with Roche (RHHBY).

Why it matters

Recursion's ability to exceed expectations and generate revenue from its partnerships is a positive sign for the company's growth potential in the competitive biotech industry. The stock jump indicates investor confidence in the company's AI-driven drug development platform and its ability to deliver on key milestones.

The details

For Q4 2025, Recursion reported $35.5 million in revenue, beating Wall Street estimates. This was largely due to a milestone payment from the company's ongoing collaboration with pharmaceutical giant Roche. Recursion is using its proprietary AI and machine learning technology to accelerate drug discovery and development.

  • Recursion reported Q4 2025 financial results on February 25, 2026.

The players

Recursion Pharmaceuticals

An AI-driven biotech company focused on accelerating drug discovery and development.

Roche

A multinational pharmaceutical and diagnostics company that is a partner of Recursion.

Got photos? Submit your photos here. ›

The takeaway

Recursion's ability to generate significant revenue from its partnerships and exceed Wall Street forecasts demonstrates the potential of its AI-powered drug discovery platform. This stock jump signals investor confidence in the company's long-term growth prospects in the competitive biotech industry.